Leiden, Netherlands-based cultivated meat company Meatable has acquired the cultivated meat platform of Uncommon Bio, a UK-based tech company that will move its focus more toward therapeutics. The deal includes critical technology, several intellectual property assets, high-performing cell lines and expert staff.
With this transaction, Meatable operates what it claims to be the only true multi-platform cultivated meat technology offering. It will integrate Uncommon Bio’s non-GMO mRNA reprogramming and saRNA differentiation technologies with its patented opti-ox system to produce cultivated meat. Benjamina Bollag, CEO of Uncommon, said in the release distributed by Meatable that the company “wanted to find the best home for our [cultivated meat] technology, and it’s exciting to see Meatable carry our work forward and apply it at scale.”
The addition of Uncommon Bio’s technology will accelerate product development for Meatable in chicken, lamb and high-flavor breeds, the release noted. It also strengthens Meatable’s intellectual property portfolio.
About the Author
Andy Hanacek
Senior Editor
Andy Hanacek has covered meat, poultry, bakery and snack foods as a B2B editor for nearly 20 years, and has toured hundreds of processing plants and food companies, sharing stories of innovation and technological advancement throughout the food supply chain. In 2018, he won a Folio:Eddie Award for his unique "From the Editor's Desk" video blogs, and he has brought home additional awards from Folio and ASBPE over the years. In addition, Hanacek led the Meat Industry Hall of Fame for several years and was vice president of communications for We R Food Safety, a food safety software and consulting company.